As Big Pharma circles RSV wagons, biotech reports mid-stage flop for its antiviral
A Phase IIb flop is casting a shadow on one biotech's efforts to take on RSV, a notoriously tough field strewn with Big Pharma rivals. Enanta Pharmaceuticals was plain about the topline data from the RSVP trial, which enrolled otherwise healthy adults with community-acquired respiratory syncytial virus. Its drug, EDP-938,